PCSK9

PCSK9

PCSK9 Overview

Molecule Name
Proprotein convertase subtilisin kexin type 9
Synonyms
PCSK9,FH3,HCHOLA3,LDLCQ1,NARC1,PC9
Drug Development Progress
Drugs in Clinical Trials36
Approved Drugs8
Highest Development StageApproved
Target Synonym
EC 3.4.21,Neural apoptosis-regulated convertase 1,Proprotein convertase 9,NARC1,PSEC0052,PCSK9,NARC-1,EC:3.4.21.-,Proprotein Convertase Subtilisin/Kexin Type 9,Subtilisin/Kexin-Like Protease PC9,PC9,Convertase Subtilisin/Kexin Type 9 Preproprotein,Hypercholesterolemia, Autosomal Dominant 3,EC 3.4.21.-,HCHOLA3,LDLCQ1,FH3,EC 3.4.21.111,Neural Apoptosis Regulated Convertase 1,FHCL3
Background
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is also known as NARC1 (neural apoptosis regulated convertase), is a newly identified subtilase belonging to the peptidase S8 subfamily. Mouse PCSK9 is synthesized as a soluble zymogen, and undergoes autocatalytic intramolecular processing in the endoplasmic reticulum, resulting in the cleavage of its propeptide that remains associated with the secreted active enzyme with a broad alkaline pH optimum. This protein plays a major regulatory role in cholesterol homeostasis. PCSK9 binds to the epidermal growth factor-like repeat A (EGF-A) domain of the low-density lipoprotein receptor (LDLR), inducing LDLR degradation. PCSK9 may also have a role in the differentiation of cortical neurons. Mutations in this gene have been associated with a rare form of autosomal dominant familial hypercholesterolemia (HCHOLA3).

PCSK9 Product List

Species
  • Human(6)
  • Cynomolgus(2)
  • Mouse(2)
  • Hamster(1)
  • Rat(1)
  • Rhesus macaque(1)
Tag
  • His Tag(8)
  • His Tag & Avi Tag(4)
  • Fc Tag(1)
Host
  • HEK293(13)
Conjugate
  • Unconjugated(9)
  • Biotin-labeled(4)
Grade
  • RUO(13)
Low Endotoxin
  • Yes(4)
  • No(9)
MoleculeCat. No.Product NameSpeciesHostStructurePurityActivitySize&Price
PCSK9
Cynomolgus PCSK9 Protein, His Tag, low endotoxin
Cynomolgus
HEK293
SDS-PAGE
ELISABLI

$270.00

50ug
PCSK9
Human PCSK9 Protein, His Tag, low endotoxin (Mass Spec & MALS verified)
Human
HEK293
MALSSDS-PAGE
ELISASPRBLI

$415.00

50ug
PCSK9
Human PCSK9 Protein, Fc Tag
Human
HEK293
SDS-PAGE
ELISABLI

$300.00

50ug
PCSK9
HOTAvitag
PC9-H82E7
Biotinylated Human PCSK9 Protein, Avitag™,His Tag (MALS verified)
Human
HEK293
MALSSDS-PAGE
ELISA

$380.00

25ug
PCSK9
Human PCSK9 (D374Y) Protein, His Tag, low endotoxin (MALS verified)
Human
HEK293
MALSSDS-PAGE
ELISASPRBLIFlow

$280.00

50ug
PCSK9
HOTAvitag
PCY-H82E7
Biotinylated Human PCSK9 (D374Y) Protein, Avitag™,His Tag
Human
HEK293
SDS-PAGE
ELISA

$360.00

25ug
PCSK9
Rhesus macaque PCSK9 Protein, His Tag
Rhesus macaque
HEK293
SDS-PAGE
ELISABLI

$270.00

50ug
PCSK9
Avitag
PC9-C82E3
Biotinylated Cynomolgus PCSK9 Protein, His,Avitag™ (MALS verified)
Cynomolgus
HEK293
MALSSDS-PAGE
ELISA

$360.00

25ug
PCSK9
Hamster PCSK9 Protein, His Tag
Hamster
HEK293
SDS-PAGE
ELISABLI

$270.00

50ug
PCSK9
Human PCSK9 Protein, C-terminal domain truncated, His Tag, low endotoxin
Human
HEK293
SDS-PAGE

$360.00

50ug
You Have Viewed 1-10 Of 13 Results
  • 1
  • 2

Can’t find what you need?

Submit your requirements and our technical
team will help.

Asset Licensing Opportunity
Resources

Clinical Drug Information

English NameResearch CodeHighest Development StageCompanyIndicationClinical Trial
Recombinant human anti-PCSK9 monoclonal antibody (Salubris)SAL003Phase 3 ClinicalShenzhen Salubris Pharmaceuticals Co Ltd
Dyslipidemias; Hypercholesterolemia; Hyperlipidemia, Familial Combined; Hyperlipidemias
Details
SYH-2053SYH2053; SYH-2053Phase 3 ClinicalCSPC Pharmaceutical Group Ltd
Dyslipidemias; Heterozygous familial hypercholesterolemia; Hypercholesterolemia; Hyperlipidemia, Familial Combined; Hyperlipidemias; Sitosterolemia
Details
RBD-7022RBD7022; RBD-7022; SR043; SR-043; QLC-7401Phase 3 ClinicalSuzhou Ribo Life Science Co Ltd
Hypercholesterolemia; Hyperlipidemia, Familial Combined; Hyperlipidemias; Sitosterolemia
Details
LaroprovstatAZD-0780; AZD0780Phase 3 ClinicalDogma Therapeutics
Atherosclerosis; Cardiovascular Diseases; Dyslipidemias; Hepatic Insufficiency; Heterozygous familial hypercholesterolemia; Renal Insufficiency
Details
Enlicitide DecanoateMK-0616Phase 3 ClinicalMerck Sharp & Dohme Corp
Arteriosclerosis; Atherosclerosis; Cardiovascular Diseases; Hepatic Insufficiency; Heterozygous familial hypercholesterolemia; Hypercholesterolemia; Hyperlipidemias; Hyperlipoproteinemia Type II; Kidney Diseases; Renal Insufficiency; Sitosterolemia
Details
AZD-8233AZD-8233; IONIS-AZ4-2.5-LRx; ION-449Phase 2 ClinicalIonis Pharmaceuticals Inc
Dyslipidemias; Hypercholesterolemia; Hyperlipidemias; Kidney Failure, Chronic
Details
CVI-LM-001CVI-LM-001; CVI-LM001; C-8304Phase 2 ClinicalXiwei'Ai Medicine Technology (Shanghai) Co Ltd
Hypercholesterolemia; Hyperlipidemias
Details
ATX-304O-304; ATX-304; O-304XPhase 2 ClinicalBetagenon Ab
Diabetes Mellitus, Type 2; Mitochondrial Diseases; Peripheral Arterial Disease
Details
MIL-86MIL-86Phase 2 ClinicalBeijing Mabworks Biotech Co Ltd
Cardiovascular Diseases; Heterozygous familial hypercholesterolemia; Hypercholesterolemia; Hyperlipidemias; Hyperlipoproteinemia Type II
Details
NNC0385-0434NNC0385-0434; NN-6435; NNC 0385 0434Phase 2 ClinicalNovo Nordisk A/S
Arteriosclerosis; Atherosclerosis; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Hypercholesterolemia; Renal Insufficiency, Chronic
Details
ARO-DIMER-PAARO-DIMER-PAPhase 2 ClinicalArrowhead Pharmaceuticals Inc
Hyperlipidemia, Familial Combined; Hyperlipidemias
Details
BEBT-701BEBT-701Phase 2 ClinicalGuangzhou BeBetter Medicine Technology Co
Hypercholesterolemia; Hyperlipidemias; Hypertension
Details
DNV-001DNV-001; DNV001Phase 2 ClinicalHangzhou Dingle New Biotechnology Co Ltd
Dyslipidemias; Hypercholesterolemia; Hyperlipidemia, Familial Combined
Details
YKYY-015YKYY015; YKYY-015Phase 2 ClinicalHangzhou Tianlong Pharmaceutical Co Ltd
Hypercholesterolemia; Hyperlipidemia, Familial Combined; Hyperlipidemias
Details
PCSK9 Inhibitors therapy(Guangdong Provincial People'S Hospital)Phase 2 ClinicalGuangdong Provincial People'S Hospital
Colorectal Neoplasms
Details
Recombinant human anti-PCSK9 monoclonal antibody (Tasly Pharm)B1655; B-1655Phase 1 ClinicalTianjin Tasly Pharmaceutical Co Ltd
Hypercholesterolemia
Details
DC-371739JYP-0739; DC-371739Phase 1 ClinicalShanghai Institute Of Materia Medica, Chinese Academy Of Sciences
Dyslipidemias; Hypercholesterolemia; Hyperlipidemias
Details
Anti-PCSK9 monoclonal antibody (Biocad)Phase 1 ClinicalBIOCAD JSC
Cardiovascular Diseases
Details
ATH-04ATH-04; Affitope AT04APhase 1 ClinicalAffiris Ag
Atherosclerosis
Details
VERVE-101VERVE-101Phase 1 ClinicalBroad Institute, Harvard University
Atherosclerosis; Cardiovascular Diseases; Heterozygous familial hypercholesterolemia; Hypercholesterolemia
Details
ART-002g1ART002g1; ART-002g1Phase 1 ClinicalShanghai Jiao Tong University Affiliated First People'S Hospital
Heterozygous familial hypercholesterolemia
Details
RN-5681RN-5681; RN5681Phase 1 ClinicalRona Therapeutics Inc
Atherosclerosis; Hypercholesterolemia
Details
PRD-001PRD001; PRD-001Phase 1 ClinicalPRD Therapeutics Inc
Fatty Liver; Homozygous familial hypercholesterolemia; Metabolic Dysfunction-Associated Steatotic Liver Disease
Details
ZRC-3306ZRC-3306Phase 1 ClinicalZydus Lifesciences Ltd
Dyslipidemias
Details
STX-1150STX1150; STX-1150Phase 1 ClinicalScribe Therapeutics Inc
Cardiovascular Diseases; Hypercholesterolemia
Details
SAL-092SAL092; SAL-092Phase 1 ClinicalShenzhen Salubris Pharmaceuticals Co Ltd
Dyslipidemias; Hypercholesterolemia
Details
VERVE-102VERVE-102Phase 1 ClinicalVerve Therapeutics Inc
Atherosclerosis; Coronary Disease; Heterozygous familial hypercholesterolemia
Details
SRSD-101SRSD101; SRSD-101; SRS001; SRS-001Phase 1 ClinicalSirius Therapeutics Inc
Cardiovascular Diseases; Hypercholesterolemia
Details
SGB-3403SGB-3403Phase 1 ClinicalSuzhou Sanegene Bio Inc
Atherosclerosis; Heterozygous familial hypercholesterolemia; Hypercholesterolemia; Hyperlipidemias
Details
RN-0191RN0191Phase 1 ClinicalDarui Biomedical Technology (Shanghai) Co Ltd
Atherosclerosis; Dyslipidemias; Hypercholesterolemia
Details
RP-910RP910; RP-910Phase 1 ClinicalRisen(Shanghai) Pharma Tech Co Ltd
Hyperlipidemias; Metabolic Diseases
Details
SAL-061YOLT-101; SAL-061; SAL061Phase 1 ClinicalShanghai Yaotang Biotechnology Co Ltd
Heterozygous familial hypercholesterolemia; Hyperlipoproteinemia Type II
Details
JX-7002JX7002; JX-7002Phase 1 ClinicalZhejiang Jingxin Pharmaceutical Co Ltd
Hypercholesterolemia; Hyperlipidemias
Details
NN-6434NN-6434Phase 1 ClinicalNovo Nordisk A/S
Details
PCSK9 modulator (Genekey Biotech)Phase 1 ClinicalShenzhen Salubris Pharmaceuticals Co Ltd
Inflammation; Metabolic Diseases
Details
ART-002(Ruizheng Gene)ART002; ART-002; ART-002(Ruizheng Gene)ClinicalRuizheng Gene (Suzhou) Co Ltd
Heterozygous familial hypercholesterolemia
Details

Marketed Drug Information

English NameResearch CodeHighest Development StageCompanyFirst Brand NameFirst Approved CountryFirst IndicationFirst Approved CompanyFirst Approved DateIndicationClinical Trial
Inclisiran sodiumALN-60212; PCSK9si; ALN-PCSsc; KJX839; KJX-839ApprovedAlnylam Pharmaceuticals IncLeqvio, 乐可为EUDyslipidemias; HypercholesterolemiaNovartis Europharm Ltd2020-12-09
Acute Coronary Syndrome; Atherosclerosis; Cardiovascular Diseases; Carotid Artery Diseases; Coronary Artery Disease; Coronary Disease; Diabetes Mellitus; Diabetes Mellitus, Type 2; Dyslipidemias; Heterozygous familial hypercholesterolemia; Homozygous familial hypercholesterolemia; Hypercholesterolemia; Hyperlipidemias; Hyperlipoproteinemia Type II; Hypolipoproteinemias; Myocardial Infarction; Renal Insufficiency; Stroke
Details
OngericimabJS-002ApprovedShanghai Junshi Biosciences Co Ltd君适达Mainland ChinaHypercholesterolemia; DyslipidemiasShanghai Junshi Biosciences Co Ltd2024-10-09
Atherosclerosis; Dyslipidemias; Heterozygous familial hypercholesterolemia; Hypercholesterolemia; Hyperlipidemia, Familial Combined; Hyperlipidemias; Hypertriglyceridemia; Neoplasms
Details
LerodalcibepLIB-003; HST 101ApprovedLib Therapeutics LlcUnited StatesHypercholesterolemiaLIB Therapeutics Inc2025-12-12
Arteriosclerosis; Atherosclerosis; Cardiovascular Diseases; Dyslipidemias; Heterozygous familial hypercholesterolemia; Homozygous familial hypercholesterolemia; Hypercholesterolemia; Hyperlipidemias; Hyperlipoproteinemia Type II; Metabolic Diseases; Stroke
Details
EbronucimabAK-102ApprovedYabao Us Pharmaceutical Co Ltd伊喜宁Mainland ChinaHypercholesterolemia; DyslipidemiasKang Rong Dongfang (Guangdong) Pharmaceutical Co Ltd2024-09-26
Dyslipidemias; Heterozygous familial hypercholesterolemia; Homozygous familial hypercholesterolemia; Hypercholesterolemia; Hyperlipidemia, Familial Combined; Hyperlipidemias; Hyperlipoproteinemia Type II
Details
RecaticimabSHR-1209ApprovedJiangsu Hengrui Medicine Co Ltd艾心安Mainland ChinaHypercholesterolemia; DyslipidemiasGuangdong Hengrui Pharmaceutical Co Ltd2025-01-08
Dyslipidemias; Hypercholesterolemia; Hyperlipidemia, Familial Combined; Hyperlipidemias; Hyperlipoproteinemia Type II; Intracranial Arteriosclerosis
Details
EvolocumabAMG-145ApprovedAmgen Inc, Astellas Pharma Inc瑞百安, RepathaEUDyslipidemias; HypercholesterolemiaAmgen Europe Bv2015-07-17
Acute Coronary Syndrome; Aortic Aneurysm, Abdominal; Atherosclerosis; Cardiovascular Diseases; Coronary Artery Disease; Coronary Disease; Diabetes Mellitus; Diabetes Mellitus, Type 2; Dyslipidemias; Glioblastoma; Glioma; Heart Failure, Systolic; Heterozygous familial hypercholesterolemia; HIV Infections; Homozygous familial hypercholesterolemia; Hypercholesterolemia; Hyperlipidemias; Hyperlipoproteinemia Type II; Myocardial Infarction; Rejection in heart transplantation; Sepsis; ST Elevation Myocardial Infarction; Stroke
Details
TafolecimabIBI-306Approved信必乐Mainland ChinaDyslipidemias; HypercholesterolemiaInnovent Biologics(Suzhou) Co Ltd2023-08-15
Aortic Valve Stenosis; Dyslipidemias; Heterozygous familial hypercholesterolemia; Homozygous familial hypercholesterolemia; Hypercholesterolemia; Hyperlipidemias
Details
Alirocumab316P; REGN-727; SAR-236553ApprovedRegeneron Pharmaceuticals Inc, Sanofi波立达, PraluentUnited StatesHypercholesterolemiaRegeneron Pharmaceuticals Inc2015-07-24
Acute Coronary Syndrome; Angina Pectoris; Atherosclerosis; Cardiovascular Diseases; Coronary Disease; Diabetes Mellitus, Type 2; Drinking Behavior; Dyslipidemias; Hemorrhage; Heterozygous familial hypercholesterolemia; HIV Infections; Homozygous familial hypercholesterolemia; Hypercholesterolemia; Hyperlipidemias; Intracranial Arteriosclerosis; Ischemic Stroke; Liver Diseases, Alcoholic; Myocardial Infarction; Plaque, Atherosclerotic; Sepsis; Shock, Septic; ST Elevation Myocardial Infarction; Stroke; Vascular Diseases
Details
Customer Reviews
  • 1***02019-10-11
    Experiment purpose: antibody screening. Experiment method: Elisa. User experience: I purchased both small and big packages. It is stable from batch to batch and has excellent bioactivity. The experiment results are also very satisfying.